MedPath

Prognostic Interest of Vasorin in Septic Shock

Not Applicable
Recruiting
Conditions
Sepsis
Acute Kidney Injury
Registration Number
NCT06072508
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Brief Summary

In septic shock, the intensity and duration of low blood pressure can lead to a critical reduction in renal tissue perfusion and lead to the onset of more or less severe Acute Kidney Injury (AKI). Vasorin (Vasn) is a protein strongly expressed in large vessels and kidneys, whose functions are still poorly known. Previous experimental studies show that Vasn is associated with decreased Angiotensin II concentrations, a vessel contractility defect and early mortality.

The investigators hypothesize that Vasn (the potential direct regulator of blood pressure) would be an early biomarker predicting the severity of AKI post septic shock, which may be associated with mortality from septic shock or lead to longer-term Chronic Renal Failure (CKD).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Age ≥18 years old.
  • Hospitalized in intensive care or medical resuscitation units.
  • With a septic shock state defined by 2 mmol/l lactate sepsis, requiring vasopressors to maintain mean blood pressure 65 mmHg (despite adequate vascular filling).
  • Whether or not they have developed AKI.
  • Patient/family information and collection of non opposition
Exclusion Criteria
  • Patients with chronic respiratory failure.
  • Pregnant women.
  • Patients in palliative care.
  • Information for the patient/someone close and collection of his opposition

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
correlation between vasorin concentration at day 3 and mortality rateday 3
correlation between vasorin concentration at day 0 and mortality rateday 0
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Amiens-Picardie

🇫🇷

Amiens, France

© Copyright 2025. All Rights Reserved by MedPath